Loss of heterozygosity of NF1 gene in juvenile chronic myelogenous leukemia with neurofibromatosis type 1

International Journal of Hematology

Volumn 68, Issue 1, 1998, Pages 53-60

  Kai, Sumio ^a   Sumita, Hiroko ^a   Fujioka, Ken Ichiro ^a   Takahashi, Hiroyuki ^a   Hanzawa, Norio ^a   Funabiki, Tetsunori ^a   Ikuta, Koichiro ^a   Sasaki, Hideki ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Juvenile chronic myelogenous leukemia; Loss of heterozygosity; Neurofibromatosis type 1; NF1 gene; Point mutation

Indexed keywords

ARTICLE; CASE REPORT; CHILD; CHROMOSOME 17Q; CHRONIC MYELOID LEUKEMIA; EXON; FIBROBLAST; GENE MUTATION; GERM LINE; HETEROZYGOSITY LOSS; HUMAN; LEUKEMIA CELL; MALE; MALIGNANT TRANSFORMATION; NEURAL CREST; NEUROFIBROMATOSIS; POINT MUTATION; PRIORITY JOURNAL;

EID: 0032127483     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0925-5710(98)00033-4     Document Type: Article

References (37)

1. Altman A.J., Palmer C.G., Baehner R.L. Juvenile chronic 'granulocytic' leukemia: a panmyelopathy with prominent monocytic involvement and circulating monocyte colony forming cells. Blood. 43:1974;341-350.
2. Castro M.H., Schaison G., Passe S.et al. Subacute and chronic myelomonocytic leukemia in children (juvenile CML): clinical and hematologic observations, and identification of prognostic factors. Cancer. 54:1984;675-686.
3. Nakamura H., Sadamori N., Ichimaru M.et al. Juvenile chronic myeloid leukemia: no rearrangement of the breakpoint cluster region. Cancer Genet Cytogenet. 36:1988;227-229.
4. Toren A., Mandel M., Amariglio N.et al. Lack of bcr rearrangement in juvenile chronic myeloid leukemia. Med Pediatr Oncol. 19:1991;493-495.
5. Ross D.W., Dent G. Juvenile chronic myeloid leukemia: oncogene characterization. Pediatr Pathol. 9:1989;669-678.
6. Gualtieri R.J., Castleberry R.P., Gibbons J.et al. Cell culture studies and oncogene expression in juvenile chronic myelogenous leukemia. Exp Hematol. 16:1988;613-619.
7. Matsui I., Tanimura M., Kobayashi N., Sawada T., Nagahara N., Akatsuka J. Neurofibromatosis type 1 and childhood cancer. Cancer. 72:1993;2746-2754.
8. Shearer P., Parham D., Kovnar E.et al. Neurofibromatosis type I and malignancy: review of 32 pediatric cases treated at a single institution. Med Pediatr Oncol. 22:1994;78-83.
9. Kaneko Y., Maseki N., Sakurai M.et al. Chromosome pattern in juvenile chronic myelogenous leukemia, myelodysplastic syndrome, and acute leukemia associated with neurofibromatosis. Leukemia. 3:1989;36-41.
10. Kelleher J.F., Carbone T.V. Monosomy 7 syndrome in an infant with neurofibromatosis. Am J Pediatr Hematol Oncol. 13:1991;338-341.
11. Shannon K.M., Watterson J., Johnson P.et al. Monosomy 7 myeloproliferative disease in children with neurofibromatosis type 1: epidemiology and molecular analysis. Blood. 79:1992;1311-1318.
12. Martin G.A., Viskochil D., Bollag G.et al. The GAP related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell. 63:1990;843-849.
13. Wallace M.R., Marchuk D.A., Andersen L.B.et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients (published erratum appears in Science 1990;250:1749). Science. 249:1990;181-186.
14. Xu G.F., Lin B., Tanaka K.et al. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell. 63:1990;835-841.
15. Ballester R., Marchuk D., Boguski M.et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell. 63:1990;851-859.
16. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
17. Orita M., Suzuki Y., Sekiya T., Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 5:1989;874-879.
18. Viskochil D., Cawthon R., O'Connell P.et al. The gene encoding the oligodendrocyte-myelin glycoprotein is embedded within the neurofibromatosis type 1 gene. Mol Cell Biol. 11:1991;906-912.
19. Bader J.L., Miller R.W. Neurofibromatosis and childhood leukemia. J Pediatr. 92:1978;925-929.
20. Mays J.A., Neerhout R.C., Bagby G.C., Koler R.D. Juvenile chronic granulocytic leukemia: emphasis on cutaneous manifestations and underlying neurofibromatosis. Am J Dis Child. 134:1980;654-658.
21. Shannon K.M., O'Connell P., Martin G.A.et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med. 330:1994;597-601.
22. Legius E., Marchuk D.A., Collins F.S., Glover T.W. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet. 3:1993;122-126.
23. Xu W., Mulligan L.M., Ponder M.A.et al. Loss of NF1 alleles in phaeochromocytomas from patients with type I neurofibromatosis. Genes Chromosom Cancer. 4:1992;337-342.
24. Gutmann D.H., Cole J.L., Stone W.J., Ponder B.A., Collins F.S. Loss of neurofibromin in adrenal gland tumors from patients with neurofibromatosis type I. Genes Chromosom Cancer. 10:1994;55-58.
25. Friedman E., Gejman P.V., Martin G.A., McCormick F. Nonsense mutations in the C-terminal SH2 region of the GTPase activating protein (GAP) gene in human tumours. Nat Genet. 5:1993;242-247.
26. Basu T.N., Gutmann D.H., Fletcher J.A., Glover T.W., Collins F.S., Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature. 356:1992;713-715.
27. Jacks T., Shih T.S., Schmitt E.M., Bronson R.T., Bernards A., Weinberg R.A. Tumour predisposition in mice heterozygous for a targeted mutation in NF1. Nat Genet. 7:1994;353-361.
28. Brannan C.I., Perkins A.S., Vogel K.S.et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev. 8:1994;1019-1029.
29. Li Y., Bollag G., Clark R.et al. Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell. 69:1992;275-281.
30. Ludwig L., Janssen J.W., Schulz A.S., Bartram C.R. Mutations within the FLR exon of NF1 are rare in myelodysplastic syndromes and acute myelocytic leukemias. Leukemia. 7:1993;1058-1060.
31. Preudhomme C., Vachee A., Quesnel B., Wattel E., Cosson A., Fenaux P. Rare occurrence of mutations of the FLR exon of the neurofibromatosis 1 (NF1) gene in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leukemia. 7:1993;1071.
32. Quesnel B., Preudhomme C., Vanrumbeke M., Vachee A., Lai J.L., Fenaux P. Absence of rearrangement of the neurofibromatosis 1 (NF1) gene in myelodysplastic syndromes and acute myeloid leukemia. Leukemia. 8:1994;878-880.
33. Kaneko H., Horiike S., Nakai H.et al. Neurofibromatosis 1 gene (NF1) mutation is a rare genetic event in myelodysplastic syndrome regardless of the disease progression. Int J Hematol. 61:1995;113-116.
34. Largaespada D.A., Brannan C.I., Jenkins N.A., Copeland N.G. Nfl deficiency causes Ras-mediated granulocyte-macrophage colony stimulating factor hypersensitvity and chronic myeloid leukaemia. Nat Genet. 12:1996;137-143.
35. Bollag G., Clapp D.W., Shih S.et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 12:1996;144-148.
36. Miyauchi J., Asada M., Sasaki M., Tsunematsu Y., Kojima S., Mizutani S. Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood. 83:1994;2248-2254.
37. Kalra R., Paderanga D.C., Olson K., Shannon K.M. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood. 84:1994;3435-3439.